<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unusual causes of peptic ulcer disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unusual causes of peptic ulcer disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unusual causes of peptic ulcer disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nimish B Vakil, MD, AGAF, FACP, FACG, FASGE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Peptic ulcers are defects in the gastrointestinal mucosa that extend through the muscularis mucosae. They persist as a function of the acid/peptic activity in gastric juice. Peptic ulcer disease remains an important cause of morbidity and mortality and health care costs [<a href="#rid1">1-3</a>]. <em>Helicobacter pylori</em> and nonsteroidal anti-inflammatory drugs (NSAIDs) account for the large majority of cases of peptic ulcer disease (PUD). (See  <a class="medical medical_review" href="/z/d/html/17.html" rel="external">"Association between Helicobacter pylori infection and duodenal ulcer"</a> and  <a class="medical medical_review" href="/z/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a>.)</p><p>This topic will review unusual causes for peptic ulcer disease. The epidemiology, risk factors, clinical manifestations, diagnosis, and management of peptic ulcer disease are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/22.html" rel="external">"Peptic ulcer disease: Epidemiology, etiology, and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/26.html" rel="external">"Peptic ulcer disease: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/24.html" rel="external">"Overview of complications of peptic ulcer disease"</a> and  <a class="medical medical_review" href="/z/d/html/25.html" rel="external">"Peptic ulcer disease: Treatment and secondary prevention"</a> and  <a class="medical medical_review" href="/z/d/html/27.html" rel="external">"Approach to refractory peptic ulcer disease"</a>.)</p><p class="headingAnchor" id="H1472020651"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In a retrospective study that included 386 patients conducted over five years in a large tertiary hospital in the United Kingdom, <em>Helicobacter pylori</em> (<em>H. pylori)</em>-negative, NSAID-negative ulcers accounted for 12 percent of all ulcers [<a href="#rid4">4</a>]. Several studies in the United States have shown that less than 75 percent of patients with duodenal ulcers (DUs) not associated with use of NSAIDs are related to <em>H. pylori </em>infection. In one study, after excluding NSAID use, 61 percent of DUs and 63 percent of gastric ulcers were <em>H. pylori</em> positive [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Non-NSAID medications</span><span class="headingEndMark"> — </span>There are a number of drugs that may cause or exacerbate peptic ulcer disease and/or upper gastrointestinal (GI) bleeding  (<a class="graphic graphic_table graphicRef79691" href="/z/d/graphic/79691.html" rel="external">table 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> – A role for acetaminophen in development of GI complications (including bleeding and perforation) has been suggested in both population-based studies and a randomized controlled trial [<a href="#rid6">6-9</a>]. As a general rule, the risk appears to be increased in doses of 2 to 3 g per day or higher. The risk also appears to be increased with the combination of NSAIDs plus high-dose acetaminophen compared with either alone [<a href="#rid6">6,9</a>]. In a randomized trial of patients with osteoarthritis, co-administration of acetaminophen and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> was not associated with a significant difference in endoscopic ulcer rates compared with either drug alone, but there were more endoscopic erosions and ulcers in the combined group compared with either alone [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bisphosphonates</strong> – Damage and acute ulceration have been observed [<a href="#rid11">11,12</a>]. Population-based studies show that use of bisphosphonates such as <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> are associated with a higher risk of upper and lower GI bleeding [<a href="#rid13">13</a>]. The risk appears to be increased substantially with co-administration of NSAIDs. (See  <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Gastrointestinal'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – The association between corticosteroids and peptic ulcer disease (PUD) and its complications is controversial with wide variations in estimates of the risk of PUD. However, the combination of glucocorticoids and NSAIDs results in a synergistic increase in the incidence of gastrointestinal events. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Gastrointestinal effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> – The antiplatelet agent clopidogrel is a significant risk factor for GI bleeding, particularly in patients with a prior risk of bleeding or on cotherapy with low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or NSAIDs [<a href="#rid14">14</a>]. The risk may also be increased with <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a>, but data are limited. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Possible early CABG'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> – Sirolimus has been associated with aggressive ulcer disease in patients undergoing liver transplantation [<a href="#rid15">15</a>]. Sirolimus is known to inhibit wound healing and has been associated with small bowel ulceration [<a href="#rid16">16</a>]. This warrants cautious use of this agent in patients with a history of PUD and aggressive management of patients on the drug who develop symptoms or complications suggestive of PUD. (See  <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors", section on 'Gastrointestinal system'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> – Spironolactone has been associated with a nearly threefold increased risk of upper GI bleeding [<a href="#rid17">17,18</a>]. The risk appears to be increased with high doses, suggesting dose-related toxicity [<a href="#rid18">18</a>]. The risk was also increased with advancing age and use of concomitant ulcerogenic medications. It is hypothesized that spironolactone, an aldosterone receptor antagonist, may cause ulceration by impairing the healing of gastric or duodenal erosions [<a href="#rid18">18</a>]. Aldosterone promotes the formation of fibrous tissue by binding to mineralocorticosteroid receptors; the effect is modulated by 11 beta hydroxysteroid dehydrogenase enzymes which are expressed in the stomach and to a small extent in the small intestine. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective serotonin</strong> <strong>reuptake inhibitors</strong> – There are increasing data suggesting an impact of selective serotonin reuptake inhibitors (SSRIs) and <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> on the risk of peptic ulcer and upper GI bleeding [<a href="#rid19">19-25</a>]. The risk of both uncomplicated PUD and ulcer-related bleeding is higher in patients taking SSRIs [<a href="#rid26">26</a>]. A concomitant <em>H. pylori</em> infection appears to increase the risk of serious upper GI bleeding in patients on SSRIs [<a href="#rid26">26</a>]. The risk of bleeding is also higher in patients with a history of peptic ulcer, with increasing age and duration of SSRI use, and when SSRIs are combined with antiplatelet therapy (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>) or NSAIDs [<a href="#rid26">26-29</a>]. In a population-based cohort study, the use of SSRIs alone or in combination with NSAIDs was not associated with an increased 30-day mortality following a peptic ulcer bleed [<a href="#rid30">30</a>]. In one large nested case-control study, the risk of upper GI bleeding was only apparent in non-users of acid inhibitors, suggesting that acid suppression attenuates the impact of SSRIs [<a href="#rid27">27</a>]. Short-time use of SSRIs (14 days) has also been associated with an increased risk of bleeding [<a href="#rid31">31</a>]. A systematic review suggested there was an approximate two-fold increase in the risk for upper GI hemorrhage in SSRI users, and the risk appears to be greatest in those using NSAIDs or antiplatelet drugs concomitantly [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Upper gastrointestinal bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antineoplastic therapy </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemotherapy </strong>– Some cancer chemotherapeutic agents have been associated with peptic disease. As an example, patients receiving continuous hepatic artery infusion of <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> frequently complain of abdominal pain. In one series, endoscopy usually revealed duodenal, gastric, or pyloric ulcerations and erosions [<a href="#rid33">33</a>]. The mechanisms have not been established; catheter migration with direct gastric infusion of chemotherapy did not explain most cases. These lesions responded to discontinuation of chemotherapy; H2 receptor blockers and proton pump inhibitors (PPIs) appeared to have little efficacy, but have not been formally tested. Thus, these ulcers may not truly be peptic ulcers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Molecular targeted therapy</strong> – An example of a targeted agent that can cause ulceration include <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, a reversible tyrosine kinase inhibitor of the epidermal growth factor receptor used for cancer treatment. GI bleeding from peptic ulcers and ulcer perforation have been reported; not surprisingly, the risk appears greater when erlotinib is combined with NSAIDs, including cyclooxygenase-2 inhibitors, and in patients with a peptic ulcer history or treated with anticoagulants [<a href="#rid34">34-37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune checkpoint inhibitors</strong> – Immune checkpoint inhibitors have been associated with severe gastritis, gastric ulcers, and GI bleeding. These ulcers and gastritis may not respond to PPI therapy, and corticosteroid therapy is needed in severe cases [<a href="#rid38">38-40</a>].</p><p></p><p class="headingAnchor" id="H19093026"><span class="h2">Infections</span></p><p class="headingAnchor" id="H4233785002"><span class="h3">Bacteria</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated duodenal</strong> <strong><em>H. pylori</em></strong> <strong>colonization</strong> – In high-prevalence regions for <em>H. pylori</em>, it is important to consider duodenal colonization in patients who lack gastric evidence of <em>H. pylori</em>. In an Italian study 42 of 608 patients (6.9 percent) with duodenal ulcer had no other obvious cause; 18 of these 42 patients had isolated duodenal colonization with <em>H. pylori </em>detected by biopsy [<a href="#rid41">41</a>]. <em>H. pylori</em> eradication therapy was given to these 18 subjects; two had ulcer recurrences compared with 14 out of 20 subjects in the "idiopathic" group. Urea breath tests were positive in only 3 of the 18 patients with isolated duodenal colonization [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-pylori helicobacter</strong> – Helicobacters other than <em>H. pylori</em> have been associated with peptic ulcer disease. <em>Helicobacter heilmannii</em> is the most frequently described organism and is often associated with antral ulcers [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H4257297187"><span class="h3">Viruses</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes simplex virus type I</strong> – The possible involvement of herpes simplex virus type 1 (HSV-1) in patients with PUD has been suggested by an increased incidence of anti-HSV-1 antibodies in patients with peptic ulcers [<a href="#rid43">43,44</a>] and the detection of DNA and protein specific for HSV-1 in the mucosa at the ulcer margin in a small proportion of patients with seemingly ordinary ulcers [<a href="#rid43">43,45</a>]. A study using polymerase chain reaction to identify HSV-I and a CLO-test and histology to identify <em>H. pylori fo</em>und HSV-I in 30 and 32 percent of duodenal and gastric ulcers, respectively [<a href="#rid46">46</a>]. HSV-I was found more frequently in the absence of <em>H. pylori </em>infection. There is some evidence that the pathogenesis may involve infected enteric neurons [<a href="#rid43">43,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'HSV esophagitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytomegalovirus</strong> – Cytomegalovirus (CMV) has been associated with ulcers in immunocompromised patients in whom it can cause multiple, large, shallow ulcerations of the stomach and esophagus [<a href="#rid48">48</a>]. The diagnosis has been made by finding intranuclear inclusion bodies or CMV-DNA in the gastric mucosa in biopsy specimens taken from the ulcerous region. (See  <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Gastrointestinal manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/3751.html" rel="external">"AIDS-related cytomegalovirus gastrointestinal disease", section on 'Gastritis'</a> and  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'CMV and EBV'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein Barr virus (EBV)</strong> – Gastric ulcers related to EBV infections have been reported in both immunocompromised and immunocompetent patients [<a href="#rid49">49,50</a>]. The endoscopic appearance may resemble malignancy.</p><p></p><p class="headingAnchor" id="H3302017632"><span class="h3">Fungi</span><span class="headingEndMark"> — </span>Fungal infections can also cause gastric ulcers in patients who are immunocompromised or immunocompetent [<a href="#rid51">51</a>]. Candidal infections have been described in isolated patients with perforated peptic ulcers. Transmural infections with the organism may be seen, and a compromised immune status may be a risk factor [<a href="#rid52">52,53</a>]. Mucormycosis can cause extensive ulceration and necrosis of the gastric wall in immunocompromised patients. Mucormycosis can cause extensive ulceration and necrosis of the gastric wall in immunocompromised patients [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Mechanical</span></p><p class="headingAnchor" id="H949657742"><span class="h3">Obstruction</span><span class="headingEndMark"> — </span>Unusual cases of duodenal ulcers have been linked to a variety of gastroduodenal abnormalities, including congenital duodenal webs, hypertrophic pyloric stenosis, annular pancreas (a rare congenital disorder in which pancreatic tissue encircles the second portion of the duodenum), and a preduodenal portal vein. Duodenal ulcers in these settings may present in infancy or childhood, but can also occur in adolescence or adulthood [<a href="#rid54">54</a>]. As an example, although annular pancreas can present at birth with high-grade duodenal obstruction, it more commonly presents in the second to seventh decade, with the peak incidence in between the ages of 30 and 40 years [<a href="#rid54">54,55</a>]. Ulcers with annular pancreas are often postbulbar and can be associated with basal acid hypersecretion, although mechanisms linking these various "obstructing" lesions of the pylorus and duodenum to acid hypersecretion and ulcer disease remain undefined. (See  <a class="medical medical_review" href="/z/d/html/5635.html" rel="external">"Annular pancreas"</a>.)</p><p class="headingAnchor" id="H1674072355"><span class="h3">Foreign body</span><span class="headingEndMark"> — </span>Peptic ulceration has also been observed in association with foreign bodies. Ingestion of multiple magnets and button batteries has been associated with GI ulceration. Microcoils from previous gastroduodenal artery embolization [<a href="#rid56">56</a>] and surgical clip migration from prior laparoscopic cholecystectomy have been found in ulcer craters [<a href="#rid57">57</a>]. Duodenal extension of a gastric trichobezoar can cause ulcerations in the duodenum (Rapunzel syndrome) [<a href="#rid58">58,59</a>]. (See  <a class="medical medical_review" href="/z/d/html/2271.html" rel="external">"Ingested foreign bodies and food impactions in adults", section on 'Disk batteries'</a> and  <a class="medical medical_review" href="/z/d/html/2271.html" rel="external">"Ingested foreign bodies and food impactions in adults", section on 'Magnets'</a>.)</p><p class="headingAnchor" id="H2486043777"><span class="h3">Post-surgical</span><span class="headingEndMark"> — </span>Stomal (marginal) ulcers involving the small intestinal mucosa occur in 1 to 16 percent of patients 3 to 18 months after Roux-en-Y gastric bypass surgery for obesity [<a href="#rid60">60-64</a>]. Patients present with pain, bleeding, or perforation. Ulcers occurring in the immediate postoperative period present with bleeding and pain, and the bleeding site can usually be reached with the standard upper endoscope. Ulcers that occur weeks or months after surgery typically present with abdominal pain after meals and are usually due to marginal ulcerations [<a href="#rid65">65</a>]. A number of causes have been suggested for marginal ulceration, including surgical technique resulting in ischemia at the anastomosis, <em>H. pylori</em> infection, and drug-induced ulceration caused by NSAIDS [<a href="#rid60">60,61</a>]. Antral exclusion (retained gastrin antrum) is a rare cause of peptic ulcers. It has been described in patients after gastric resection when some antral mucosa was retained in the duodenal pouch [<a href="#rid66">66</a>]. </p><p class="headingAnchor" id="H2434860301"><span class="h2">Acid hypersecretory states</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrinoma</strong> – The classic tetrad of the Zollinger-Ellison syndrome consists of a non-beta islet cell tumor secreting gastrin in association with acid hypersecretion and severe PUD, which occurs in approximately 90 percent of cases. (See  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">The majority of Zollinger-Ellison tumors are sporadic. However, 20 to 25 percent occur in association with the multiple endocrine neoplasia syndrome type 1 (MEN1). MEN1 is a familial disorder characterized by an autosomal dominant predisposition to tumors of the parathyroid glands (which occur in nearly all patients by age 50), anterior pituitary, and pancreatic islet cells (gastrinoma or insulinoma). (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Although gastrinoma-associated peptic ulcers may be indistinguishable from ordinary peptic ulcers, several distinguishing features should raise the level of suspicion  (<a class="graphic graphic_table graphicRef50291" href="/z/d/graphic/50291.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic mastocytosis</strong> – Systemic mastocytosis is characterized by mast cell infiltration of many tissues and symptoms of flushing, pruritus, abdominal pain, and diarrhea. Dyspepsia, duodenal ulcers, and severe duodenitis occur in 30 to 50 percent of cases and can be associated with basal acid hypersecretion, a presentation sometimes reminiscent of gastrinoma [<a href="#rid67">67</a>]. While fasting, serum gastrin levels are normal, serum histamine concentrations may be elevated, particularly in the setting of ulcer disease, suggesting that circulating histamine contributes to basal acid hypersecretion [<a href="#rid67">67,68</a>]. (See  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloproliferative disorders</strong> – Acid hypersecretion, an increased risk of peptic ulcer, and elevated serum histamine concentrations occur in rare myeloproliferative disorders associated with basophilia such as basophilic leukemia and chronic myeloid leukemia with marked basophilia [<a href="#rid69">69</a>]. Acid hypersecretion may only occur when cell lysis occurs during chemotherapy [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1">Polycythemia vera has also been associated with peptic disease. The precipitating cause may be reduced mucosal blood flow due to increased viscosity. A study suggested that patients with polycythemia vera are at greater risk for <em>H. pylori</em> infection and have a higher prevalence of ulcers and erosions in the stomach and duodenum than controls without the disease [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera", section on 'Gastrointestinal symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antral G-cell hyperfunction</strong> – In the pre-<em>H. pylori</em> era, an entity called antral G-cell hyperfunction was reported, characterized by duodenal ulcers, increased basal- and/or meal-stimulated gastrin release, and usually increased basal or maximal acid output [<a href="#rid71">71,72</a>]. It now appears probable that antral G-cell hyperfunction usually reflects an exaggerated response to <em>H. pylori</em>-induced hypergastrinemia, being part of the spectrum of <em>H. pylori</em>-associated duodenal ulcers. In <em>H. pylori</em>-positive patients who appear to have this disorder, anti-<em>H. pylori</em> therapy induces ulcer healing and suppresses serum gastrin levels [<a href="#rid72">72-74</a>]. Although controversial and rare, antral G-cell hyperfunction can probably occur in the absence of <em>H. pylori</em> [<a href="#rid72">72,74</a>]. The pathogenesis of hypergastrinemia in this setting is not known.</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Ischemic</span></p><p class="headingAnchor" id="H483282604"><span class="h3">Arterial/venous diseases</span><span class="headingEndMark"> — </span>Mucosal blood flow is critical to mucosal integrity. Although ischemia is rare because of the rich vascularization of the gastroduodenal mucosa, vascular insufficiency syndromes involving arterial supply rarely present with peptic ulceration that is unrelated to <em>H. pylori</em> infection or NSAID use [<a href="#rid75">75-78</a>]. Some patients complain of typical ulcer pain, while others may have symptoms suggestive of mesenteric angina with pain following meals. Endoscopy may reveal multiple gastric or duodenal ulcers. Ulcers related to vascular stenosis often fail PPI therapy, but several reports indicated response to revascularization [<a href="#rid75">75,78</a>]. Gastroduodenal artery pseudoaneurysm is also a rare cause of ulceration [<a href="#rid79">79</a>].</p><p>Intestinal ulceration can occur after vascular injury by abdominal radiotherapy, with the second portion of the duodenum being especially sensitive to radiation injury [<a href="#rid80">80</a>]. Gastroduodenal ulceration also occurs following chemoembolization used to treat hepatic tumors with an incidence between 3 and 5 percent; abdominal pain, nausea, vomiting, and anorexia herald this complication [<a href="#rid81">81-83</a>]. Careful attention to protocol may reduce the risks of this complication [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/z/d/html/7054.html" rel="external">"Overview of gastrointestinal toxicity of radiation therapy", section on 'Gastritis'</a>.)</p><p class="headingAnchor" id="H3267637695"><span class="h3">Non-occlusive ischemia</span><span class="headingEndMark"> — </span>Mucosal vasoconstriction may explain the perforation of gastroduodenal ulcers that have been described with crack cocaine use [<a href="#rid84">84-88</a>]. Enterocolic lymphocytic phlebitis is a rare cause of GI ischemia apparently due to inflammation. It usually involves the intestine, but one case had both gastric and duodenal involvement associated with a chronic non-healing antral ulcer [<a href="#rid89">89</a>].</p><p>Hypothermia and hypoxia at high altitudes may also predispose to gastric and duodenal erosions and ulcers [<a href="#rid90">90,91</a>]. </p><p class="headingAnchor" id="H19093401"><span class="h2">Inflammatory and infiltrating disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sarcoidosis</strong> – Involvement of the stomach is the most common site of sarcoidosis in the GI tract, almost always occurring in association with pulmonary disease [<a href="#rid92">92,93</a>]. Ulceration resembling PUD can occur with or without enlargement of mucosal folds. (See  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crohn</strong> <strong>disease</strong> – Crohn disease of the stomach and/or duodenum is not infrequently found [<a href="#rid94">94</a>] but only occasionally causes clinical impact. In the large majority of cases, more distal Crohn disease is also evident. Involvement presents with obstruction, ulceration, fistula formation, or bleeding [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Other gastrointestinal features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other gastroenteritides</strong> – Case reports indicate that peptic ulcers, including perforated ulcers, can occur in association with eosinophilic gastroenteritis [<a href="#rid96">96-98</a>] and hypereosinophilic syndromes [<a href="#rid99">99</a>]. Refractory gastric ulcers have also been associated with abundant IgG4-positive plasma cell infiltration and granulomatosis with polyangiitis [<a href="#rid100">100,101</a>]. (See  <a class="medical medical_review" href="/z/d/html/2536.html" rel="external">"Eosinophilic gastrointestinal diseases"</a> and  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H19093422"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic hypersecretory duodenal</strong> <strong>ulcer</strong> – Approximately 10 percent of patients with duodenal ulcers have basal acid output above 15 mmol per hour, normal serum gastrin levels, and ulcer disease unrelated to <em>H. pylori</em> infection [<a href="#rid102">102</a>]. These cases appear to represent a form of hypersecretory duodenal ulcer, the mechanisms of which remain to be defined. The acid hypersecretion appears to respond to long-term treatment with a PPI [<a href="#rid102">102,103</a>]. Such patients may require relatively high doses of a PPI, as in gastrinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stress</strong> <strong>ulcers</strong> <strong>in the intensive care</strong> <strong>unit</strong> – Estimates of the incidence of overt GI bleeding from stress-induced ulceration range from 1.5 to 8.5 percent among all intensive care unit patients, but may be as high as 15 percent among patients who do not receive stress ulcer prophylaxis. Patient selection for prophylaxis is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1611.html" rel="external">"Stress ulcers in the intensive care unit: Diagnosis, management, and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H1283392129"><span class="h1">EVALUATION OF H. PYLORI AND NSAID NEGATIVE ULCERS</span><span class="headingEndMark"> — </span>Before considering unusual causes of peptic ulcer disease (PUD), <em>H. pylori</em> and NSAID use should be excluded since these two risk factors still account for the large majority of cases of PUD. False-negative testing for <em>H. pylori</em> and a failure to detect NSAID use are probably the most common causes of apparently <em>H. pylori</em>-negative, NSAID-negative ulcers. For <em>H. pylori</em>, particular caution is needed because many of the patients being evaluated will have been treated with a proton pump inhibitor or antibiotics, rendering tests dependent upon bacterial density less reliable. </p><p class="headingAnchor" id="H3723850198"><span class="h2">History</span><span class="headingEndMark"> — </span>The initial evaluation for patients with non-<em>H. pylori</em>, non-NSAID related peptic ulcer disease should include an assessment for associated diseases as well as other possible comorbidities.</p><p>Some of the key elements of the history include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Medications (including over-the-counter drugs and supplements).</p><p class="bulletIndent1"><span class="glyph">●</span>Cocaine or methamphetamine use.</p><p class="bulletIndent1"><span class="glyph">●</span>Prior gastric surgery including bariatric procedures or radiation.</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities including Crohn disease, sarcoidosis, mastocytosis, multiple endocrine neoplasia type 1 (MEN1).</p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant history of a hematologic disease including chronic myeloid leukemia and polycythemia vera.</p><p class="bulletIndent1"><span class="glyph">●</span>Associated symptoms, especially diarrhea which may be due to Zollinger-Ellison syndrome, Crohn disease, or systemic mastocytosis.</p><p class="bulletIndent1"><span class="glyph">●</span>A history of peptic ulcers that are resistant to medical therapy, recurrent ulcers, multiple ulcers beyond the duodenal bulb, which are suggestive of Zollinger-Ellison Syndrome (ZES)  (<a class="graphic graphic_table graphicRef50291" href="/z/d/graphic/50291.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of peptic ulcer disease or MEN1 may indicate the presence of ZES.</p><p></p><p>If an unusual cause of a peptic ulcer is suspected based on the history, additional testing should be performed as needed to establish the etiology. </p><p class="headingAnchor" id="H3503750477"><span class="h2">Laboratory testing in selected patients</span><span class="headingEndMark"> — </span>Initial evaluation in a patient with suspected ZES is with measurement of fasting serum gastrin concentration and measurement of gastric pH  (<a class="graphic graphic_table graphicRef50291" href="/z/d/graphic/50291.html" rel="external">table 2</a>). In patients with elevated serum gastrin levels/low gastric pH that are not diagnostic for ZES, we perform a <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">secretin</a> stimulation test. Laboratory evaluation for ZES is discussed in detail separately. (See <a class="local">'History'</a> above and <a class="local">'Acid hypersecretory states'</a> above and  <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H1360864190"><span class="h2">Repeat upper endoscopy in ulcers without a clear etiology</span><span class="headingEndMark"> — </span>In patients with gastric or duodenal ulcers without a clear etiology, we perform an upper endoscopy 8 to 12 weeks after initiating medical therapy (with biopsies of the ulcer if still present) in order to exclude a malignancy. This upper endoscopy allows for additional biopsies of the ulcer to exclude neoplastic, infiltrative, or infectious causes of ulceration. We biopsy both the ulcers and the surrounding mucosa. In addition, we biopsy the duodenum to detect isolated duodenal colonization by <em>H. pylori</em>. (See <a class="local">'Bacteria'</a> above and <a class="local">'Inflammatory and infiltrating disease'</a> above.)</p><p class="headingAnchor" id="H4034588706"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117855.html" rel="external">"Society guideline links: Peptic ulcer disease"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Peptic ulcers are defects in the gastrointestinal mucosa that extend through the muscularis mucosae. They persist as a function of the acid/peptic activity in gastric juice. Peptic ulcer disease (PUD) is an important cause of morbidity and health care costs. <em>Helicobacter pylori</em> and NSAIDs account for the large majority of cases of peptic ulcer disease. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several medications have been implicated in the development of peptic ulcers either alone or synergistically with other ulcerogenic or antithrombotic agents. Drugs implicated include <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> (in doses greater than 2 or 3 g daily), bisphosphonates, cocaine, glucocorticoids, selective serotonin reuptake inhibitors, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, and <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>. The risk of some agents may only be evident in patients with an ulcer or bleeding diathesis, such as those with a prior history of PUD or bleeding complications. (See <a class="local">'Non-NSAID medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other causes of peptic ulcer disease include infections (eg, non-pylori Helicobacter, Cytomegalovirus), mechanical (eg, post-obstructive, foreign body, surgery), ischemia, inflammatory and infiltrating diseases of the stomach (eg, Crohn disease), and acid hypersecretory states (eg, Zollinger-Ellison syndrome). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Before considering unusual causes of peptic ulcer disease, <em>H. pylori</em> and NSAID use should be excluded since these two risk factors still account for the large majority of cases of PUD. False-negative testing for <em>H. pylori</em> and a failure to detect NSAID use are probably the most common causes of apparently <em>H. pylori</em>-negative, NSAID-negative ulcers. For <em>H. pylori</em>, particular caution is needed because many of the patients being evaluated will have been treated with a proton pump inhibitor or antibiotics, rendering tests dependent upon bacterial density less reliable. (See <a class="local">'Evaluation of H. pylori and NSAID negative ulcers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial evaluation for patients with non-<em>H. pylori</em>, non-NSAID related peptic ulcer disease should include an assessment for associated diseases as well as other possible comorbidities. Zollinger-Ellison Syndrome should be suspected in patients with multiple or refractory peptic ulcers; ulcers distal to the duodenum; peptic ulcer disease and diarrhea, enlarged gastric folds, or multiple endocrine neoplasia type 1 (MEN1). ZES should also be suspected in patients with peptic ulcer disease and a family history of peptic ulcer disease or MEN1. (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with gastric or duodenal ulcers without a clear etiology, we perform an upper endoscopy 8 to 12 weeks after initiating medical therapy (with biopsies of the ulcer if still present) in order to exclude a malignancy. This upper endoscopy allows for additional biopsies of the ulcer to exclude neoplastic, infiltrative, or infectious causes of ulceration. We biopsy both the ulcers and the surrounding mucosa. In addition, we biopsy the duodenum to detect isolated duodenal colonization by <em>H. pylori. </em>(See <a class="local">'Repeat upper endoscopy in ulcers without a clear etiology'</a> above.)</p><p></p><p class="headingAnchor" id="H452563582"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Andrew H. Soll, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143:1179.</a></li><li><a class="nounderline abstract_t">Peery AF, Crockett SD, Barritt AS, et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology 2015; 149:1731.</a></li><li><a class="nounderline abstract_t">Tsoi AH, Garg M, Tsoi EH. Peptic Ulcer Disease: An Unusual Presentation of a Common Problem. Gastroenterology 2022; 162:e2.</a></li><li><a class="nounderline abstract_t">Musumba C, Jorgensen A, Sutton L, et al. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther 2012; 36:48.</a></li><li><a class="nounderline abstract_t">Jyotheeswaran S, Shah AN, Jin HO, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998; 93:574.</a></li><li><a class="nounderline abstract_t">Rahme E, Barkun A, Nedjar H, et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008; 103:872.</a></li><li><a class="nounderline abstract_t">García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12:570.</a></li><li><a class="nounderline abstract_t">González-Pérez A, Rodríguez LA. Upper gastrointestinal complications among users of paracetamol. Basic Clin Pharmacol Toxicol 2006; 98:297.</a></li><li><a class="nounderline abstract_t">Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis 2011; 70:1534.</a></li><li><a class="nounderline abstract_t">Boike JR, Kao R, Meyer D, et al. Does concomitant use of paracetamol potentiate the gastroduodenal mucosal injury associated with aspirin? A prospective, randomised, pilot study. Aliment Pharmacol Ther 2012; 36:391.</a></li><li><a class="nounderline abstract_t">Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999; 13:515.</a></li><li><a class="nounderline abstract_t">Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002; 162:936.</a></li><li><a class="nounderline abstract_t">Peng YL, Hu HY, Luo JC, et al. Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. Osteoporos Int 2014; 25:1617.</a></li><li><a class="nounderline abstract_t">Lin CC, Hu HY, Luo JC, et al. Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study. Aliment Pharmacol Ther 2013; 38:1119.</a></li><li><a class="nounderline abstract_t">Smith AD, Bai D, Marroquin CE, et al. Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. Clin Transplant 2005; 19:250.</a></li><li><a class="nounderline abstract_t">Altomare JF, Smith RE, Potdar S, Mitchell SH. Delayed gastric ulcer healing associated with sirolimus. Transplantation 2006; 82:437.</a></li><li><a class="nounderline abstract_t">Gulmez SE, Lassen AT, Aalykke C, et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol 2008; 66:294.</a></li><li><a class="nounderline abstract_t">Verhamme K, Mosis G, Dieleman J, et al. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ 2006; 333:330.</a></li><li><a class="nounderline abstract_t">Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163:59.</a></li><li><a class="nounderline abstract_t">Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 27:31.</a></li><li><a class="nounderline abstract_t">Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7:1314.</a></li><li><a class="nounderline abstract_t">Dunn NR, Pearce GL, Shakir SA. Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding. BMJ 2000; 320:1405.</a></li><li><a class="nounderline abstract_t">Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006; 23:937.</a></li><li><a class="nounderline abstract_t">Vidal X, Ibáñez L, Vendrell L, et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008; 31:159.</a></li><li><a class="nounderline abstract_t">Anglin R, Yuan Y, Moayyedi P, et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109:811.</a></li><li><a class="nounderline abstract_t">Dall M, Schaffalitzky de Muckadell OB, Møller Hansen J, et al. Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors. Scand J Gastroenterol 2011; 46:1039.</a></li><li><a class="nounderline abstract_t">de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65:795.</a></li><li><a class="nounderline abstract_t">Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183:1835.</a></li><li><a class="nounderline abstract_t">Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hallas J. There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: a population-based case-control study. Aliment Pharmacol Ther 2010; 32:1383.</a></li><li><a class="nounderline abstract_t">Gasse C, Christensen S, Riis A, et al. Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding. Scand J Gastroenterol 2009; 44:1288.</a></li><li><a class="nounderline abstract_t">Wang YP, Chen YT, Tsai CF, et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014; 171:54.</a></li><li><a class="nounderline abstract_t">Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13:42.</a></li><li><a class="nounderline abstract_t">Shike M, Gillin JS, Kemeny N, et al. Severe gastroduodenal ulcerations complicating hepatic artery infusion chemotherapy for metastatic colon cancer. Am J Gastroenterol 1986; 81:176.</a></li><li><a class="nounderline abstract_t">Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Pharmacol 2010; 70:908.</a></li><li><a class="nounderline abstract_t">Togashi Y, Masago K, Fujita S, et al. Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer 2011; 74:98.</a></li><li><a class="nounderline abstract_t">Fidler MJ, Argiris A, Patel JD, et al. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 2008; 14:2088.</a></li><li><a class="nounderline abstract_t">Reckamp K, Gitlitz B, Chen LC, et al. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer 2011; 117:809.</a></li><li><a class="nounderline abstract_t">Haryal A, Townsend MJ, Baskaran V, et al. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer 2023; 129:367.</a></li><li><a class="nounderline abstract_t">Tang T, Abu-Sbeih H, Luo W, et al. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol 2019; 54:538.</a></li><li><a class="nounderline abstract_t">Liu WT, Li YF, Hsieh TY. Unusual severe gastritis and gastric ulcers caused by pembrolizumab. J Postgrad Med 2022; 68:38.</a></li><li><a class="nounderline abstract_t">Pietroiusti A, Forlini A, Magrini A, et al. Isolated H. pylori duodenal colonization and idiopathic duodenal ulcers. Am J Gastroenterol 2008; 103:55.</a></li><li><a class="nounderline abstract_t">Debongnie JC, Donnay M, Mairesse J, et al. Gastric ulcers and Helicobacter heilmannii. Eur J Gastroenterol Hepatol 1998; 10:251.</a></li><li><a class="nounderline abstract_t">Löhr JM, Nelson JA, Oldstone MB. Is herpes simplex virus associated with peptic ulcer disease? J Virol 1990; 64:2168.</a></li><li><a class="nounderline abstract_t">Archimandritis A, Markoulatos P, Tjivras M, et al. Herpes simplex virus types 1 and 2 and cytomegalovirus in peptic ulcer disease and non-ulcer dyspepsia. Hepatogastroenterology 1992; 39:540.</a></li><li><a class="nounderline abstract_t">Kemker BP Jr, Docherty JJ, De Lucia A, et al. Herpes simplex virus: a possible etiologic agent in some gastroduodenal ulcer disease. Am Surg 1992; 58:775.</a></li><li><a class="nounderline abstract_t">Tsamakidis K, Panotopoulou E, Dimitroulopoulos D, et al. Herpes simplex virus type 1 in peptic ulcer disease: an inverse association with Helicobacter pylori. World J Gastroenterol 2005; 11:6644.</a></li><li><a class="nounderline abstract_t">Gesser RM, Valyi-Nagy T, Fraser NW, Altschuler SM. Oral inoculation of SCID mice with an attenuated herpes simplex virus-1 strain causes persistent enteric nervous system infection and gastric ulcers without direct mucosal infection. Lab Invest 1995; 73:880.</a></li><li><a class="nounderline abstract_t">Kang SH, Lee KM, Shin SJ, et al. Cytomegalovirus Gastric Ulcer Complicated with Pyloric Obstruction in a Patient with Ulcerative Colitis. Korean J Gastroenterol 2017; 69:359.</a></li><li><a class="nounderline abstract_t">Gwak JW, Yoo J, Suh SO, et al. Benign Gastric Ulcer with Epstein-Barr Virus Infection Mimicking Malignant Gastric Ulcer. Korean J Gastroenterol 2019; 73:177.</a></li><li><a class="nounderline abstract_t">Catinean A, Motocu R, Fetica B, Mezei A. Epstein-Barr virus-associated gastric ulcer mimicking gastric neoplasia: a case report. Med Ultrason 2019; 21:96.</a></li><li><a class="nounderline abstract_t">Termos S, Othman F, Alali M, et al. Total Gastric Necrosis Due to Mucormycosis: A Rare Case of Gastric Perforation. Am J Case Rep 2018; 19:527.</a></li><li><a class="nounderline abstract_t">Ukekwe FI, Nwajiobi C, Agbo MO, et al. Candidiasis, A Rare Cause of Gastric Perforation: A Case Report and Review of Literature. Ann Med Health Sci Res 2015; 5:314.</a></li><li><a class="nounderline abstract_t">Gupta N. A rare cause of gastric perforation-Candida infection: a case report and review of the literature. J Clin Diagn Res 2012; 6:1564.</a></li><li><a class="nounderline abstract_t">Naylor RG, Juler GL. Congenital causes of duodenal ulcers in adults. Arch Surg 1976; 111:658.</a></li><li><a class="nounderline abstract_t">Urayama S, Kozarek R, Ball T, et al. Presentation and treatment of annular pancreas in an adult population. Am J Gastroenterol 1995; 90:995.</a></li><li><a class="nounderline abstract_t">Craig DG, Sebastian S, Hashmi S. Electronic clinical challenges and images in GI. Duodenal ulcer owing to erosion of microcoils from previous gastroduodenal artery embolization. Gastroenterology 2008; 135:e5.</a></li><li><a class="nounderline abstract_t">Samim MM, Armstrong CP. Surgical clip found at duodenal ulcer after laparoscopic cholecystectomy: report of a case. Int J Surg 2008; 6:473.</a></li><li><a class="nounderline abstract_t">Iwama I, Nambu R, Hara T. A novel finding of Rapunzel syndrome. Clin J Gastroenterol 2018; 11:19.</a></li><li><a class="nounderline abstract_t">Parakh JS, McAvoy A, Corless DJ. Rapunzel syndrome resulting in gastric perforation. Ann R Coll Surg Engl 2016; 98:e6.</a></li><li><a class="nounderline abstract_t">Hedberg J, Hedenström H, Nilsson S, et al. Role of gastric acid in stomal ulcer after gastric bypass. Obes Surg 2005; 15:1375.</a></li><li><a class="nounderline abstract_t">Rasmussen JJ, Fuller W, Ali MR. Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients. Surg Endosc 2007; 21:1090.</a></li><li><a class="nounderline abstract_t">Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery. Surg Obes Relat Dis 2006; 2:455.</a></li><li><a class="nounderline abstract_t">Azagury DE, Abu Dayyeh BK, Greenwalt IT, Thompson CC. Marginal ulceration after Roux-en-Y gastric bypass surgery: characteristics, risk factors, treatment, and outcomes. Endoscopy 2011; 43:950.</a></li><li><a class="nounderline abstract_t">Pyke O, Yang J, Cohn T, et al. Marginal ulcer continues to be a major source of morbidity over time following gastric bypass. Surg Endosc 2019; 33:3451.</a></li><li><a class="nounderline abstract_t">Eisendrath P, Deviere J. Major complications of bariatric surgery: endoscopy as first-line treatment. Nat Rev Gastroenterol Hepatol 2015; 12:701.</a></li><li><a class="nounderline abstract_t">Gibril F, Lindeman RJ, Abou-Saif A, et al. Retained gastric antrum syndrome: a forgotten, treatable cause of refractory peptic ulcer disease. Dig Dis Sci 2001; 46:610.</a></li><li><a class="nounderline abstract_t">Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988; 95:657.</a></li><li><a class="nounderline abstract_t">Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:579.</a></li><li><a class="nounderline abstract_t">Anderson W, Helman CA, Hirschowitz BI. Basophilic leukemia and the hypersecretion of gastric acid and pepsin. Gastroenterology 1988; 95:195.</a></li><li><a class="nounderline abstract_t">Torgano G, Mandelli C, Massaro P, et al. Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori. Br J Haematol 2002; 117:198.</a></li><li><a class="nounderline abstract_t">Cooper RG, Dockray GJ, Calam J, Walker R. Acid and gastrin responses during intragastric titration in normal subjects and duodenal ulcer patients with G-cell hyperfunction. Gut 1985; 26:232.</a></li><li><a class="nounderline abstract_t">Annibale B, De Magistris L, Corleto V, et al. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. Aliment Pharmacol Ther 1994; 8:87.</a></li><li><a class="nounderline abstract_t">Annibale B, Rindi G, D'Ambra G, et al. Antral gastrin cell hyperfunction and Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10:607.</a></li><li><a class="nounderline abstract_t">Kwan CP, Tytgat GN. Antral G-cell hyperplasia: a vanishing disease? Eur J Gastroenterol Hepatol 1995; 7:1099.</a></li><li><a class="nounderline abstract_t">Somin M, Korotinski S, Attali M, et al. Three cases of chronic mesenteric ischemia presenting as abdominal pain and Helicobacter pylori-negative gastric ulcer. Dig Dis Sci 2004; 49:1990.</a></li><li><a class="nounderline abstract_t">Gómez-Rubio M, Opio V, Acín F, et al. Chronic mesenteric ischemia: a cause of refractory duodenal ulcer. Am J Med 1995; 98:308.</a></li><li><a class="nounderline abstract_t">Patel VK, Barrison I, Jackson J, Catnach S. Gastric ulceration due to chronic mesenteric ischaemia treated by stenting of the inferior mesenteric artery. Gut 2005; 54:888.</a></li><li><a class="nounderline abstract_t">Becker S, Bonderup OK, Fonslet TO. Ischaemic gastric ulceration with endoscopic healing after revascularization. Eur J Gastroenterol Hepatol 2006; 18:451.</a></li><li><a class="nounderline abstract_t">Elazary R, Abu-Gazala M, Schlager A, et al. Therapeutic angiography for giant bleeding gastro-duodenal artery pseudoaneurysm. World J Gastroenterol 2010; 16:1670.</a></li><li><a class="nounderline abstract_t">Koop H, Koop I, Klein M, et al. Irradiation-induced duodenal ulcer disease refractory to ranitidine: healing by omeprazole. J Clin Gastroenterol 1989; 11:631.</a></li><li><a class="nounderline abstract_t">Naymagon S, Warner RR, Patel K, et al. Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature. Dig Dis Sci 2010; 55:2450.</a></li><li><a class="nounderline abstract_t">Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc 2009; 70:561.</a></li><li><a class="nounderline abstract_t">South CD, Meyer MM, Meis G, et al. Yttrium-90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol 2008; 6:93.</a></li><li><a class="nounderline abstract_t">Lee HS, LaMaute HR, Pizzi WF, et al. Acute gastroduodenal perforations associated with use of crack. Ann Surg 1990; 211:15.</a></li><li><a class="nounderline abstract_t">Abramson DL, Gertler JP, Lewis T, Kral JG. Crack-related perforated gastropyloric ulcer. J Clin Gastroenterol 1991; 13:17.</a></li><li><a class="nounderline abstract_t">Sharma R, Organ CH Jr, Hirvela ER, Henderson VJ. Clinical observation of the temporal association between crack cocaine and duodenal ulcer perforation. Am J Surg 1997; 174:629.</a></li><li><a class="nounderline abstract_t">Arrillaga A, Sosa JL, Najjar R. Laparoscopic patching of crack cocaine-induced perforated ulcers. Am Surg 1996; 62:1007.</a></li><li><a class="nounderline abstract_t">Kram HB, Hardin E, Clark SR, Shoemaker WC. Perforated ulcers related to smoking "crack" cocaine. Am Surg 1992; 58:293.</a></li><li><a class="nounderline abstract_t">Abraham SC, Solem CA, Hauser SC, Smyrk TC. Chronic antral ulcer associated with gastroduodenal lymphocytic phlebitis. Am J Surg Pathol 2004; 28:1659.</a></li><li><a class="nounderline abstract_t">Berríos J, Sedano O, Calle E, et al. [Upper digestive hemorrhage in the inhabitants of high altitudes in Peru]. Rev Gastroenterol Peru 1996; 16:13.</a></li><li><a class="nounderline abstract_t">Wu TY, Ding SQ, Liu JL, et al. High-altitude gastrointestinal bleeding: an observation in Qinghai-Tibetan railroad construction workers on Mountain Tanggula. World J Gastroenterol 2007; 13:774.</a></li><li><a class="nounderline abstract_t">Fireman Z, Sternberg A, Yarchovsky Y, et al. Multiple antral ulcers in gastric sarcoid. J Clin Gastroenterol 1997; 24:97.</a></li><li><a class="nounderline abstract_t">Farman J, Ramirez G, Rybak B, et al. Gastric sarcoidosis. Abdom Imaging 1997; 22:248.</a></li><li><a class="nounderline abstract_t">Oberhuber G, Hirsch M, Stolte M. High incidence of upper gastrointestinal tract involvement in Crohn's disease. Virchows Arch 1998; 432:49.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Allan RN, Keighley MR. An audit of gastroduodenal Crohn disease: clinicopathologic features and management. Scand J Gastroenterol 1999; 34:1019.</a></li><li><a class="nounderline abstract_t">Siaw EK, Sayed K, Jackson RJ. Eosinophilic gastroenteritis presenting as acute gastric perforation. J Pediatr Gastroenterol Nutr 2006; 43:691.</a></li><li><a class="nounderline abstract_t">Chehade M, Sicherer SH, Magid MS, et al. Multiple exudative ulcers and pseudopolyps in allergic eosinophilic gastroenteritis that responded to dietary therapy. J Pediatr Gastroenterol Nutr 2007; 45:354.</a></li><li><a class="nounderline abstract_t">Tee HP, Swartz D, Tydd T, Leong RW. Gastrointestinal: Eosinophilic enteritis manifesting as brown-pigmented duodenal ulcers. J Gastroenterol Hepatol 2009; 24:1892.</a></li><li><a class="nounderline abstract_t">Park TY, Choi CH, Yang SY, et al. A case of hypereosinophilic syndrome presenting with intractable gastric ulcers. World J Gastroenterol 2009; 15:6129.</a></li><li><a class="nounderline abstract_t">Fujita T, Ando T, Sakakibara M, et al. Refractory gastric ulcer with abundant IgG4-positive plasma cell infiltration: a case report. World J Gastroenterol 2010; 16:2183.</a></li><li><a class="nounderline abstract_t">Malik M, Ismail M, Pattanaik D. Granulomatosis With Polyangiitis Presenting as Gastric Ulcer: An Unusual Initial Manifestation Successfully Treated With Rituximab. Am J Med Sci 2015; 350:338.</a></li><li><a class="nounderline abstract_t">Hirschowitz BI, Mohnen J, Shaw S. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10:507.</a></li><li><a class="nounderline abstract_t">Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005; 3:39.</a></li></ol></div><div id="topicVersionRevision">Topic 23 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22885331" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Burden of gastrointestinal disease in the United States: 2012 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26327134" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34186062" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Peptic Ulcer Disease: An Unusual Presentation of a Common Problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22554233" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9576450" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18371130" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11505178" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16611205" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Upper gastrointestinal complications among users of paracetamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804100" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22742578" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Does concomitant use of paracetamol potentiate the gastroduodenal mucosal injury associated with aspirin? A prospective, randomised, pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215737" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Alendronate gastric ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966346" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gastric and duodenal safety of daily alendronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24566586" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24099473" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740563" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906046" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Delayed gastric ulcer healing associated with sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18507655" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840442" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Spironolactone and risk of upper gastrointestinal events: population based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12523917" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919277" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19716436" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858059" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16573796" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217791" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777151" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21554164" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606952" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21948719" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21050241" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19891579" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030313" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24993365" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2937289" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Severe gastroduodenal ulcerations complicating hepatic artery infusion chemotherapy for metastatic colon cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21175447" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Erlotinib and pantoprazole: a relevant interaction or not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21377230" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381949" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20922800" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36377339" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31079556" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34121670" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Unusual severe gastritis and gastric ulcers caused by pembrolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764496" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Isolated H. pylori duodenal colonization and idiopathic duodenal ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9585030" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Gastric ulcers and Helicobacter heilmannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2157877" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Is herpes simplex virus associated with peptic ulcer disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1336474" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Herpes simplex virus types 1 and 2 and cytomegalovirus in peptic ulcer disease and non-ulcer dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1456606" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Herpes simplex virus: a possible etiologic agent in some gastroduodenal ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16425358" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Herpes simplex virus type 1 in peptic ulcer disease: an inverse association with Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558851" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Oral inoculation of SCID mice with an attenuated herpes simplex virus-1 strain causes persistent enteric nervous system infection and gastric ulcers without direct mucosal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28637105" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cytomegalovirus Gastric Ulcer Complicated with Pyloric Obstruction in a Patient with Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31013561" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Benign Gastric Ulcer with Epstein-Barr Virus Infection Mimicking Malignant Gastric Ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779839" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Epstein-Barr virus-associated gastric ulcer mimicking gastric neoplasia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29724988" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Total Gastric Necrosis Due to Mucormycosis: A Rare Case of Gastric Perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26229723" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Candidiasis, A Rare Cause of Gastric Perforation: A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23285460" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A rare cause of gastric perforation-Candida infection: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1275697" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Congenital causes of duodenal ulcers in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7771437" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Presentation and treatment of annular pancreas in an adult population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19013170" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Electronic clinical challenges and images in GI. Duodenal ulcer owing to erosion of microcoils from previous gastroduodenal artery embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059149" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Surgical clip found at duodenal ulcer after laparoscopic cholecystectomy: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29067636" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A novel finding of Rapunzel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26688419" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rapunzel syndrome resulting in gastric perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354514" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Role of gastric acid in stomal ulcer after gastric bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17514403" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16925380" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ulcer disease after gastric bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21997722" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Marginal ulceration after Roux-en-Y gastric bypass surgery: characteristics, risk factors, treatment, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30543040" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Marginal ulcer continues to be a major source of morbidity over time following gastric bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26347162" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Major complications of bariatric surgery: endoscopy as first-line treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11318541" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Retained gastric antrum syndrome: a forgotten, treatable cause of refractory peptic ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3396814" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Gastrointestinal dysfunction in systemic mastocytosis. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10909042" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Gastrointestinal abnormalities and involvement in systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3131179" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Basophilic leukemia and the hypersecretion of gastric acid and pepsin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11918555" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3972270" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acid and gastrin responses during intragastric titration in normal subjects and duodenal ulcer patients with G-cell hyperfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8186351" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8853766" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Antral gastrin cell hyperfunction and Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8680911" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Antral G-cell hyperplasia: a vanishing disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15628740" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Three cases of chronic mesenteric ischemia presenting as abdominal pain and Helicobacter pylori-negative gastric ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872350" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Chronic mesenteric ischemia: a cause of refractory duodenal ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888802" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Gastric ulceration due to chronic mesenteric ischaemia treated by stenting of the inferior mesenteric artery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16538121" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ischaemic gastric ulceration with endoscopic healing after revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20355248" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Therapeutic angiography for giant bleeding gastro-duodenal artery pseudoaneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2573627" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Irradiation-induced duodenal ulcer disease refractory to ranitidine: healing by omeprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20198431" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19577743" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18764938" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Yttrium-90 microsphere induced gastrointestinal tract ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403771" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Acute gastroduodenal perforations associated with use of crack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2007737" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Crack-related perforated gastropyloric ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409587" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical observation of the temporal association between crack cocaine and duodenal ulcer perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8955237" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Laparoscopic patching of crack cocaine-induced perforated ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1622009" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Perforated ulcers related to smoking "crack" cocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577689" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Chronic antral ulcer associated with gastroduodenal lymphocytic phlebitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664481" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : [Upper digestive hemorrhage in the inhabitants of high altitudes in Peru].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278202" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : High-altitude gastrointestinal bleeding: an observation in Qinghai-Tibetan railroad construction workers on Mountain Tanggula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9077726" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Multiple antral ulcers in gastric sarcoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9107643" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Gastric sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9463587" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : High incidence of upper gastrointestinal tract involvement in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10563673" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : An audit of gastroduodenal Crohn disease: clinicopathologic features and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130750" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Eosinophilic gastroenteritis presenting as acute gastric perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873749" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Multiple exudative ulcers and pseudopolyps in allergic eosinophilic gastroenteritis that responded to dietary therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002943" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Gastrointestinal: Eosinophilic enteritis manifesting as brown-pigmented duodenal ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20027690" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A case of hypereosinophilic syndrome presenting with intractable gastric ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20440861" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Refractory gastric ulcer with abundant IgG4-positive plasma cell infiltration: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26191640" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Granulomatosis With Polyangiitis Presenting as Gastric Ulcer: An Unusual Initial Manifestation Successfully Treated With Rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8853754" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15645403" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
